[Care pathway to diagnosis in fibromyalgia and inflammatory rheumatic diseases: A patient-centered approach using a comparative mixed-methods study]

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis

Changes in Descending Pain Modulation During Anti-Tumor Necrosis Factor Therapy: A Prospective Study in Rheumatoid Arthritis and Spondyloarthritis

Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice

Granulocytes and monocytes apheresis for polyarthritis in a multimorbid patient

Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts

SerpinA3N limits cartilage destruction in osteoarthritis by inhibiting macrophage-derived leucocyte elastase

Management perspectives from patients with fibromyalgia experiences with the healthcare pathway: a qualitative study

Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital

Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment

Novel pathogenic variants in SLCO2A1 causing autosomal dominant primary hypertrophic osteoarthropathy

Évaluation systématique de la réponse humorale contre le SARS-CoV-2 dans une cohorte française de 283 patients atteints d’un rhumatisme inflammatoire chronique

Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases

Evaluation of Patients With Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic

Comparison of ultrasonography and radiography of the wrist for diagnosis of calcium pyrophosphate deposition

Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?

Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases

Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease

Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection

Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients

Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française

Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy

Characteristics of JIA-associated uveitis at the age of transition

Intestinal barrier biomarkers in adult patients with juvenile idiopathic arthritis in transition

Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood

Comparison of subcutaneous and oral methotrexate initiation in rheumatoid arthritis in current practice

Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis

Failure of conventional treatment and losartan in Camurati-Engelmann disease: A case report

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study